Immunosuppression

Immunosuppression Basics - Immune Taming 101

• Goal: Prevent graft rejection while minimizing drug toxicity & infection risk. Balance efficacy with safety.
• Mechanism: Modulate or suppress the recipient's immune response to the foreign allograft.
• Types of Rejection:
  • Hyperacute: Mins-hrs; pre-formed antibodies (e.g., ABO, HLA).
  • Acute: Days-months; T-cell mediated (cellular) or antibody-mediated (humoral).
  • Chronic: Months-years; multifactorial, slow progressive graft dysfunction.

⭐ Acute cellular rejection, primarily T-cell mediated, is the most common type of rejection in the first few months post-transplant and is often reversible with treatment.

Immunosuppressant Drugs - The Pill Powerhouse

• Key Classes & Actions:
  • Calcineurin Inhibitors (CNIs): ↓IL-2 gene transcription.
    • Cyclosporine: Nephrotoxic, hypertension, gingival hyperplasia, hirsutism. 📌 CsA's 4H's: Hyperplasia (gingival), Hirsutism, Hypertension, Harmful to kidneys.
    • Tacrolimus (FK506): Potent. Nephro/neurotoxic, NODAT.
  • Antimetabolites: Inhibit lymphocyte proliferation.
    • Azathioprine: Prodrug 6-MP. Myelosuppression (TPMT).
    • Mycophenolate (MMF/MPA): Inhibits IMPDH. GI upset, myelosuppression. Teratogenic.
  • mTOR Inhibitors: ↓IL-2 signaling.
    • Sirolimus (Rapamycin): Hyperlipidemia, poor wound healing, pneumonitis.
  • Corticosteroids (e.g., Prednisolone): Broad anti-inflammatory, ↓cytokines.
  • Biologics:
    • Basiliximab (anti-CD25 mAb): IL-2R antagonist (induction).
    • Alemtuzumab (anti-CD52 mAb): Lymphocyte depletion.

⭐ Mycophenolate Mofetil (MMF) is a prodrug, rapidly converted to mycophenolic acid (MPA), which selectively inhibits inosine monophosphate dehydrogenase (IMPDH), crucial for de novo purine synthesis in lymphocytes.

Immunosuppressive Protocols - Protocol Parade

• Induction (Peri-transplant): Intense early immunosuppression to prevent acute rejection.
  • Agents: Monoclonal Abs (Basiliximab - IL-2R Ab), Polyclonal Abs (ATG/ALG), Alemtuzumab (CD52 Ab).
• Maintenance (Lifelong): Long-term prevention of acute & chronic rejection, ensuring graft survival.
  • Triple therapy: CNI (Tacrolimus/Cyclosporine) + Antiproliferative (Mycophenolate Mofetil [MMF]/Azathioprine [AZA]) + Corticosteroids. 📌 Mnemonic: CNI + Anti-Pro + Steroids.
• Rejection Treatment:
  • Acute Cellular Rejection (ACR): High-dose pulse steroids; ATG for steroid-refractory cases.
  • Antibody-Mediated Rejection (AMR): Multi-modal: Plasmapheresis, IVIG, Rituximab, Bortezomib.

⭐ Tacrolimus is generally preferred over Cyclosporine due to better efficacy and fewer cosmetic side effects (e.g., hirsutism, gingival hyperplasia).

Monitoring Therapy - The Watchful Eye

• Goal: Optimize immunosuppression, balancing efficacy against toxicity.
• Core Monitoring:
  • Therapeutic Drug Monitoring (TDM): Essential for narrow therapeutic index drugs.
    • Tacrolimus (Trough): 5-15 ng/mL.
    • Cyclosporine (Trough C0): 100-400 ng/mL.
    • Sirolimus (Trough): 4-12 ng/mL.
  • Graft function: Serial labs (e.g., creatinine, LFTs).
  • Biopsy: For suspected rejection (gold standard).
  • Non-invasive: Donor-derived cell-free DNA (dd-cfDNA).

⭐ TDM for Calcineurin Inhibitors (Tacrolimus, Cyclosporine) is crucial to prevent allograft rejection while avoiding dose-related toxicities like nephrotoxicity.

Complications & Risks - Side Effect Storm

A delicate balance: graft survival vs. patient health due to numerous side effects.

• Infections: ↑ risk opportunistic (CMV, PJP, BK virus). Prophylaxis crucial.
• Malignancies: ↑ Post-Transplant Lymphoproliferative Disorder (PTLD), skin cancers (SCC > BCC).
• Metabolic Syndrome: Steroid-induced diabetes, HTN, dyslipidemia.
• Drug-Specific Toxicities:
  • CNIs (Tacrolimus, Cyclosporine): Nephrotoxicity, neurotoxicity, HTN.
  • Mycophenolate: GI upset, myelosuppression.
  • Steroids: Cushingoid features, osteoporosis.

⭐ PTLD is often EBV-driven in transplant patients.

High‑Yield Points - ⚡ Biggest Takeaways

• Triple therapy (CNI, antimetabolite, steroid) is standard for maintenance immunosuppression.
• Tacrolimus & Cyclosporine (CNIs) cause nephrotoxicity, neurotoxicity, and hypertension.
• Mycophenolate Mofetil (MMF) is preferred over Azathioprine; key side effect: GI intolerance.
• Basiliximab (anti-CD25 mAb) is a common induction agent targeting IL-2 receptors.
• Acute rejection: primarily T-cell mediated. Chronic rejection: multifactorial, often antibody-mediated components.
• Prophylaxis for CMV and Pneumocystis jirovecii Pneumonia (PJP) is critical.
• mTOR inhibitors (Sirolimus) cause hyperlipidemia, mouth ulcers, and impaired wound healing.